Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Document Type
Year range
Neurology Perspectives ; 1(1):104-106, 2021.
Article in English, Spanish | Scopus | ID: covidwho-1959883
Horizonte Medico ; 21(3):1DUMMT, 2021.
Article in Spanish | EMBASE | ID: covidwho-1485685


Objective: To determine the epidemiological characteristics of COVID-19 patients treated at the Emergency Department of the Hospital Militar Central Luis Arias Schreiber from July to October 2020. Materials and methods: A descriptive, observational and cross-sectional study was carried out with 89 patients who tested positive for SARS-CoV-2 on molecular and/or rapid tests. The information was collected from the daily progress report of the patients treated at the hospital’s Emergency Department from July to October 2020. The results were processed using the IBM SPSS Statistics V25.0. Results: Males were more likely to test positive for COVID-19 (84.27 %). Most cases occurred in patients aged between 50 and 59 (34.83 %). The highest percentage of deaths was found in patients older than 70 years, out of whom 71.43 % were females. Comorbidities were reported in patients aged 40 and older, out of whom 67.41 % had at least one of them. Obesity was the most frequent comorbidity, followed by hypertension and type 2 diabetes mellitus. Sixty-seven point four one percent (67.41 %) of the patients required non-invasive ventilation and most of them were hospitalized. Twenty-one point three four percent (21.34 %) of the patients required mechanic ventilation and 68.42 % were admitted to the intensive care unit. Conclusions: The most common characteristics of COVID-19 patients are male sex, ages between 50 and 59 years old, and obesity. Additionally, using non-invasive ventilation had a better prognosis than using mechanical ventilation.

Journal of Thoracic Oncology ; 16(10):S883-S884, 2021.
Article in English | EMBASE | ID: covidwho-1474794


Introduction: There are currently no predictive biomarkers for long-term survival after neoadjuvant chemoimmunotherapy. However, the identification of non-small lung cancer (NSCLC) patients who obtain long-term benefit from chemoimmunotherapy is essential to optimize therapies. Methods: Using samples from NADIM clinical trial (NCT03081689), in which resectable stage IIIA NSCLC patients were treated with neoadjuvant chemo-immunotherapy with nivolumab, we have evaluated the capacity of ctDNA levels before treatment initiation to predict overall survival (OS) and progression-free survival (PFS) by calculating Harrell’s C-statistic and we compare its predictive value with classical survival surrogates as the pathological response and clinical response assessed according to RECIST criteria v.1.1. The ctDNA was analyzed by NGS, using the Oncomine Pan-Cancer Cell-Free Assay™ (Thermo Fisher Scientific®). To explore the prognostic value of the amount of ctDNA at baseline, for each positive plasma sample, we calculated the sum of the mutant allele frequency (MAF) for all detected mutations. Patients who died from COVID19 were excluded from this analysis. Results: In our study, clinical responses based on RECIST criteria were not predictive for OS or PFS. On the contrary, in the multivariate analysis, patients with low ctDNA levels (<1% MAF), in the baseline sample, had significantly improved PFS and OS than patients in whom the opposite situation occurred (adjusted HR: 0.22;95%CI: 0.06-0.75;P=0.016 and adjusted HR: 0.04;95%CI: 0.00-0.45;P=0.008 for PFS and OS, respectively). The adjusted C-statistic (c) to predict PFS for ctDNA was 0.68 (95%CI: 0.51-0.84), which was superior to that of RECIST criteria (c=0.61;95%CI: 0.45-0.78) and similar to that of pathological response (c=0.68;95%CI: 0.52-0.84). Similarly, baseline ctDNA levels predicted OS (c=0.85;95%CI: 0.72-0.99) better than RECIST criteria (c=0.68;95%CI: 0.44-0.93). Conclusion: Pre-treatment ctDNA levels predicted more accurately long-term survival than radiological assessments in NADIM study and might be useful for the design of new clinical trials.